Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-282988
Filing Date
2025-11-14
Accepted
2025-11-14 16:15:44
Documents
47
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tcrt-20250930.htm   iXBRL 10-Q 1535453
2 EX-31.1 tcrt-ex31_1.htm EX-31.1 14381
3 EX-32.1 tcrt-ex32_1.htm EX-32.1 8056
  Complete submission text file 0001193125-25-282988.txt   5791609

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20250930.xsd EX-101.SCH 1052382
49 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20250930_htm.xml XML 676966
Mailing Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301
Business Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33038 | Film No.: 251486469
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)